ATIS is on the move! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move!

ATIS 0.1000

-47.4%

Apr 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Marshall Teitelbaum who wrote (1242)	12/18/1997 5:05:00 PM
From: Harry D. Kramer	Read Replies (2) of 2205

Marshall, according to the news today we also have ORG's Apligraf to be reviewed by the FDA Panel in January. Stock made a nice move against the market. ATIS on the other hand remained very weak. I am really surprised why we haven't seen more short covering. IMO, going into the panel with a short position is a strategy not worth the risk. I can't find any reason for the panel to deny recommendation. ATIS at $13 is no bargain, but I still expect a positive move after a panel recommendation in January. What are the arguments of the shorts??? Apart from the fact that ATIS is not cheap. Good things are not supposed to be cheap, right? All in all, biotech is quite dead. No surprise, though. With a fresh desaster every day it's hard to lure new investors into the group. Surprised to hear your profit expectations on Regranex. By the way, didn't you promise me that my X-mas wish would be fulfilled? ($15!?!) I guess we have to delay X-mas into January this time. :-) Harry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next